Global And Country-level Burden Of Heart Failure Secondary To Chagas Disease 1990-2019: An Analysis Of The Global Burden Of Disease Study

Yosef Manla,Obada Kholoki,Feras Bader,Mahmoud Traina

DOI: https://doi.org/10.1016/j.cardfail.2023.10.369

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction The burden of Chagas disease (CD) is expanding in non-endemic areas (Figure.1), yet CD remains underdiagnosed. Patients with the disease may eventually develop cardiac manifestations, resulting in CD heart failure (CD-HF). Little is known about the global burden of CD-HF; therefore, we aim to investigate the global and country-level trends in prevalence and years lived with disability (YLD) due to CD-HF between 1990-2019. Methods Data on the prevalence and YLDs (defined as years lived in less-than-ideal health) due to HF and HF-CD for the years 1990-2019 were extracted from the 2019 Global Burden of Disease (GBD) study and were reported as numbers, rates, and age-standardized rates. In addition, we compared countries' prevalence and YLDs due to CD-HF worldwide. GBD Compare tool was used to generate maps characterizing the burden of CD-HF. Results Approximately 0.5% of all prevalent HF cases globally were attributed to CD in 2019. In the last mentioned year, there were 283,235.8 (uncertainty interval (UI) [181,831.7- 407,164.6] prevalent cases of HF-CD, corresponding to a decrease of 11% (4.1 to 3.66 per 100,000) in the rate of HF-CD prevalence, and a 35% reduction (5.2 to 3.4 per 100,000) in the age-standardized rates between 1990-2019. In the last two decades, there has been significant growth in the prevalence of CD-HF in non-endemic countries, including Ireland, Spain, Italy, and Japan, among others. In addition, there was an almost 2:1 male predominance with a rate of 4.8 vs. 2.5 prevalent cases per 100,000 globally in 2019. In the same year, the number of years lived with disability due to CD-HF globally was 16,113.55 (95%UI [8,657.5- 26,705.4]), corresponding to a decrease of 11% in the rate of YLDs (0.23 to 0.21 years per 100,000) and a reduction of 35% (0.3 to 0.19 years per 100,000) in the age-standardized rate of YLDs between 1990-2019. While the highest number of prevalent cases and YLDs were recorded in Brazil, Mexico, and Argentina (Figure.2), countries with the highest rates of prevalence and YLD due to CD-HF were Bolivia, Chile, and Venezuela (Figure.1). Conclusion Despite the reduction in the global burden of CD-HF in the last three decades, the expanding burden to non-endemic regions warrants all stakeholders to work together to develop strategies to improve screening and timely management of CD-HF.

cardiac & cardiovascular systems